This is a preprint.
Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque
- PMID: 38645086
- PMCID: PMC11030404
- DOI: 10.1101/2024.04.10.588902
Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque
Update in
-
Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque.Placenta. 2025 Jun 13;166:103-108. doi: 10.1016/j.placenta.2024.09.013. Epub 2024 Sep 20. Placenta. 2025. PMID: 39362807 Free PMC article.
Abstract
Nanoparticles offer promise as a mechanism to non-invasively deliver targeted placental therapeutics. Our previous studies utilizing intraplacental administration demonstrate efficient nanoparticle uptake into placental trophoblast cells and overexpression of human IGF1 ( hIGF1 ). Nanoparticle-mediated placental overexpression of hIGF1 in small animal models of placental insufficiency and fetal growth restriction improved nutrient transport and restored fetal growth. The objective of this pilot study was to extend these studies to the pregnant nonhuman primate and develop a method for local delivery of nanoparticles to the placenta via maternal blood flow from the uterine artery. Nanoparticles containing hIGF1 plasmid driven by the placenta-specific PLAC1 promoter were delivered to a mid-gestation pregnant rhesus macaque via a catheterization approach that is clinically used for uterine artery embolization. Maternal-fetal interface, fetal and maternal tissues were collected four days post-treatment to evaluate the efficacy of hIGF1 treatment in the placenta. The uterine artery catheterization procedure and nanoparticle treatment was well tolerated by the dam and fetus through the four-day study period following catheterization. Nanoparticles were taken up by the placenta from maternal blood as plasmid-specific hIGF1 expression was detected in multiple regions of the placenta via in situ hybridization and qPCR. The uterine artery catheterization approach enabled successful delivery of nanoparticles to maternal circulation in close proximity to the placenta with no concerns to maternal or fetal health in this short-term feasibility study. In the future, this delivery approach can be used for preclinical evaluation of the long-term safety and efficacy of nanoparticle-mediated placental therapies in a rhesus macaque model.
Highlights: Novel method to deliver therapeutics to maternal-fetal interfaceDelivery of nanoparticles to the placenta via maternal catheterization.
Similar articles
-
Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque.Placenta. 2025 Jun 13;166:103-108. doi: 10.1016/j.placenta.2024.09.013. Epub 2024 Sep 20. Placenta. 2025. PMID: 39362807 Free PMC article.
-
Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention.Physiol Genomics. 2025 Jan 1;57(1):8-15. doi: 10.1152/physiolgenomics.00131.2024. Epub 2024 Oct 7. Physiol Genomics. 2025. PMID: 39374081 Free PMC article.
-
Maternal, placental and fetal response to a non-viral, polymeric nanoparticle gene therapy in nonhuman primates.bioRxiv [Preprint]. 2023 Dec 14:2023.06.16.545278. doi: 10.1101/2023.06.16.545278. bioRxiv. 2023. Update in: Mol Hum Reprod. 2024 Nov 14;30(11):gaae038. doi: 10.1093/molehr/gaae038. PMID: 38168281 Free PMC article. Updated. Preprint.
-
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review.Genes (Basel). 2021 Aug 17;12(8):1255. doi: 10.3390/genes12081255. Genes (Basel). 2021. PMID: 34440429 Free PMC article. Review.
-
Nanomedicines: An approach to treat placental insufficiency and the current challenges.J Control Release. 2023 Aug;360:57-68. doi: 10.1016/j.jconrel.2023.06.003. Epub 2023 Jun 21. J Control Release. 2023. PMID: 37330012 Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous